Related Experiment Video
Updated: May 5, 2026
05:14
A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
Published on: May 16, 2020
4.5K
Implementing Precision Medicine for Dilated Cardiomyopathy: Insights from The DCM Consortium.
Elizabeth Jordan1,2, Hanyu Ni1,2, Patricia Parker1,2
1The Davis Heart and Lung Research Institute, The Ohio State University, Columbus, OH.
Medrxiv : the Preprint Server for Health Sciences
|December 9, 2024
Summary
Clinical genetic evaluation for dilated cardiomyopathy (DCM) faces barriers. Addressing these challenges is crucial for advancing precision medicine in heart failure care.
Area of Science:
- Cardiovascular Medicine
- Genetics
- Precision Medicine
Background:
- Clinical genetic evaluation for dilated cardiomyopathy (DCM) is inconsistently applied.
- Identifying barriers to genetic testing is essential for improving precision medicine in DCM care.
Purpose of the Study:
- To assess the current state of genetic evaluation practices for DCM in advanced heart failure/transplant (HF/TX) programs.
- To identify needs and barriers hindering the implementation of genetic evaluations for DCM.
Main Methods:
- An online survey was distributed to cardiologist investigators in US HF/TX programs.
- A subsequent in-person discussion was held with participants to gather further insights.
Main Results:
- All surveyed HF/TX programs conduct clinical genetic testing for DCM, with variable annual uptake.
- Significant barriers include lack of selection criteria, limited provider ordering autonomy, and challenges in accessing genetics services.
- Key themes identified were knowledge gaps, cost concerns, family care barriers, and infrastructure limitations.
Conclusions:
- HF/TX programs encounter substantial implementation challenges in providing DCM genetic evaluations.
- Targeted strategies are necessary to overcome these barriers and facilitate precision medicine for DCM.
Related Concept Videos
01:29Pharmacogenomics: Identification of New Drug Targets
129
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
129
01:25Cardiomyopathy I: Introduction and Classification
828
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
828
01:30Cardiomyopathy II: Dilated Cardiomyopathy
798
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
798
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
810
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
810
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
957
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
957
01:29Cardiomyopathy V: Interprofessional Care
761
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
761